RUXOLITINIB for Psoriasis: Side Effects & Safety Data
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
There are 29 adverse event reports in the FDA FAERS database where RUXOLITINIB was used for Psoriasis.
Most Reported Side Effects for RUXOLITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 12,492 | 18.3% | 1,527 | 1,769 |
| Death | 6,561 | 9.6% | 6,541 | 687 |
| Fatigue | 5,663 | 8.3% | 280 | 1,124 |
| Anaemia | 3,593 | 5.3% | 539 | 1,438 |
| Haemoglobin decreased | 3,297 | 4.8% | 456 | 1,306 |
| Platelet count decreased | 3,028 | 4.4% | 540 | 1,198 |
| Diarrhoea | 2,531 | 3.7% | 193 | 827 |
| Asthenia | 2,529 | 3.7% | 305 | 949 |
| Dizziness | 2,398 | 3.5% | 102 | 587 |
| Pneumonia | 2,343 | 3.4% | 643 | 1,726 |
| Headache | 2,271 | 3.3% | 97 | 541 |
| Product availability issue | 2,142 | 3.1% | 20 | 188 |
| Product dose omission issue | 2,130 | 3.1% | 41 | 281 |
| Dyspnoea | 2,042 | 3.0% | 258 | 886 |
| Splenomegaly | 1,995 | 2.9% | 292 | 686 |
Other Indications for RUXOLITINIB
Myelofibrosis (21,650)
Polycythaemia vera (12,352)
Myeloproliferative neoplasm (2,982)
Product used for unknown indication (2,869)
Graft versus host disease (2,291)
Primary myelofibrosis (2,234)
Essential thrombocythaemia (1,788)
Chronic graft versus host disease (1,679)
Acute lymphocytic leukaemia (1,105)
Vitiligo (1,053)
Other Drugs Used for Psoriasis
APREMILAST (76,127)
SECUKINUMAB (58,471)
ADALIMUMAB (56,634)
RISANKIZUMAB-RZAA (40,890)
ETANERCEPT (30,483)
USTEKINUMAB (21,763)
IXEKIZUMAB (16,569)
GUSELKUMAB (11,736)
CERTOLIZUMAB PEGOL (8,179)
METHOTREXATE (6,628)